Profundus Imaging

Pioneering eye diagnostics with telescope technology

There are over 1 billion individuals globally that suffer from a vision impairment that could have or has yet to be prevented. There is a strong demand for imaging of retinal structures on a cellular level, such as photoreceptors and capillaires, in order to improve diagnosis of retinal disease and prevent vision loss.


We will make a difference

Retinal disease in general affects the structural integrity of the retina. Early detection of such structural changes is therefore in high demand in order to minimize disease induced damage and suffering.

Several diseases give changes in the retina, one example is diabetes. Diabetic eye screening test can find problems before they affect the sight. The earlier problems are found the earlier treatment and life style changes can be recommended.


The Profundus Guide Star System will be customized with different modules that will improve clinical workflow and save valuable time. Image post-processing and longitudinal trend reports will  facilitate evaluation and follow-up.

”Profundus has a unique method for being able to look at the cellular level in the retina, which should be able to generate significant benefits in research and also clinically for large patient groups.”


Prof. Anders Kvanta, Karolinska Institute

A life science startup founded in Sweden


Profundus AB was founded on the results of research and development of a unique instrument for wide-field high-resolution adaptive optics retinal imaging, by the Adaptive Optics research team at the Department of Ophthalmology,  University of Gothenburg. 


The prototype features a 7x7 deg corrected field-of-view that enables the user to quickly cover larger retinal areas. An 11x11 deg mosaic can easily be obtained  using only five images. The diagnostic benefit of the proof-of-concept prototype is currently being documented in a clinical research program.

 

Our aim is to provide researchers and clinicians with a tool that can visualize currently subclinical changes of retinal disease.

Partners and collaborations